VPT:CC - Ventripoint Whitepaper Distribution:
(TheNewswire)
Dr. Alvira Macanovic outlines thebenefits of using AI to overcome sparse data and transform ultrasoundimages into MRI-quality heart images
Toronto, Ontario — January 3, 2024— Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ( OTC:VPTDF),now bringing its AI-powered heart-scanning technology to the world’shospitals, is delighted to release acomprehensive white paper, authored by Dr. Alvira Macanovic, the CEOand President of the company, Cristina Almeida, BScKin (Hons.), RDCSAE, PE (Clinical Applications Lead), and Desmond Hirson, MEng(Technology Advisor).
The white paper outlining the proven reliability of Ventripoint’sAI-powered technology to turn ultrasounds into MRI-quality images ofthe heart is being distributed to current and future partners. It hasalso been published by Canada Health Watch , a media platform covering advances in health care.
Dr. Macanovic's white paper focuses on a long-standingchallenge in cardiac ultrasound: how to achieve clear and accurateimaging of the heart, particularly the right ventricle (RV)?Traditional methods like two-dimensional echocardiography (2DE) havebeen limited in their ability to accurately measure chamber size andfunction due to imaging complexities.
Ventripoint’s AI technology augments sparse data fromultrasounds by tapping into a vast library of cardiac MRI images,resulting in MRI-quality images that previously were not reliablyattainable.
“The purpose of our white paper is to indicate tocardiologists and hospital administrators that Ventripoint’stechnology has solved this problem and is a reliable diagnostic tooltransforming ultrasound scans into MRI-quality images of the heart,”said Dr. Macanovic. “We are not trying to replace MRIs, but we canaugment patient and physicians’ access to heart scans at a fractionof the time and cost of an MRI, improving health outcomes as well assaving hospital and clinical resources.”
Central to this white paper is the VMS+ Knowledge-BasedReconstruction Algorithm, an AI-driven innovation advanced under theoversight of Dr. Macanovic, a Ph.D. who has focused on designing anddeveloping medical devices, with nearly 20 years in medical technologycommercialization.
With Ventripoint’s AI technology — now beingcommercialized and used in hospitals and clinics — only a smallnumber of predefined anatomical points from ultrasound images arerequired to generate accurate heart measurements, offering precisionon par with cardiac MRI (cMRI) scans.
This novel approach brings multiple advantages. Itsurpasses traditional imaging methods in accuracy and speed. With theVMS+ system, echo scans are cheaper and quicker than cMRI, enablingmore widespread and routine cardiac monitoring, crucial for earlydetection and intervention in heart conditions.
The practical application of the VMS+ system, which isconstantly being upgraded, has been validated through its consistentand reliable performance, making it a new tool for accurate diagnosisand treatment in cardiac care. This is especially significant inregions where advanced imaging technologies like cMRI are lessaccessible.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe, and Canada.
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placedon the forward-looking statements and information because the Companycan give no assurance that they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to several factors andrisks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.